HealthcareServices

Global Visceral Leishmaniasis Industry Trends and Market Forecast 2026–2030

March 4, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the visceral leishmaniasis market from 2026–2035 with trusted insights from The Business Research Company

What size range is anticipated for the Visceral Leishmaniasis Market from 2026 to 2030?

The visceral leishmaniasis market has shown significant expansion in recent years. It is anticipated to grow from $1.06 billion in 2025 to $1.12 billion in 2026, reflecting a compound annual growth rate (CAGR) of 5.9%. The growth observed in the historic period is largely attributable to the expansion of endemic disease prevalence, increasing public health awareness initiatives, availability of established antiparasitic treatments, growth of hospital-based treatment programs, and international health organization support.

The visceral leishmaniasis market is anticipated to experience robust growth in the coming years, reaching $1.39 billion by 2030, with a compound annual growth rate (CAGR) of 5.5%. This projected expansion during the forecast period is due to factors such as increased investments in novel therapeutics, a rising focus on vaccine and immunotherapy development, the broader adoption of molecular diagnostics, growing government funding for disease elimination efforts, and improved access to treatment in endemic regions. Significant trends during this period are expected to include the increasing use of advanced diagnostic techniques, a rise in the application of combination drug therapies, a heightened emphasis on early disease detection, the expansion of public health screening programs, and enhanced investment in treatment accessibility.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23573&type=smp

What Drivers Are Affecting Demand In The Visceral Leishmaniasis Market?

The escalating issue of malnutrition is projected to boost the visceral leishmaniasis market’s expansion. Malnutrition refers to a state of health where the body receives inadequate or imbalanced nutrient intake, crucial for healthy physiological functioning. The surge in malnutrition can be attributed to food insecurity, which restricts access to wholesome food, resulting in undernourishment and a lack of vital micronutrients, thereby weakening the immune system. Compromised immune function due to malnutrition renders the body more susceptible to various infections, including visceral leishmaniasis. Inadequate nutrient levels diminish the body’s natural defense mechanisms, escalating the likelihood of severe illness and associated complications. As an illustration, the United Nations Children’s Fund (UNICEF), a U.S.-based specialized agency, reported in July 2024 that approximately 733 million individuals worldwide faced undernourishment in 2023. Consequently, the escalating incidence of malnutrition is acting as a key driver for the expansion of the visceral leishmaniasis market.

Which Segment Groups Are Influencing The Visceral Leishmaniasis Market?

The visceral leishmaniasis market covered in this report is segmented –

1) By Treatment: Antiparasitic, Antifungal, Other Treatments

2) By Diagnosis Method: Serological Tests, Molecular Tests, Microscopy, Culture Methods

3) By Route Of Administration: Oral, Injectable, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

5) By End-User: Hospitals, Homecare, Specialty Clinics, Other End-Users

Subsegments:

1) By Antiparasitic: Pentavalent Antimonials, Miltefosine, Paromomycin, Sitamaquine, Combination Therapy

2) By Antifungal: Amphotericin B, Liposomal Amphotericin B (AmBisome), Azoles, Echinocandins, Polyenes

3) By Other Treatments: Immunotherapy, Monoclonal Antibodies, Vaccine-Based Approaches, Photodynamic Therapy, Gene Therapy

Which Innovation Trends Are Advancing Developments Within The Visceral Leishmaniasis Market?

Companies active in the visceral leishmaniasis market are prioritizing the development of enhanced treatment alternatives, such as antiparasitic drugs, to elevate their effectiveness and improve patient availability, particularly in endemic regions. Antiparasitic drugs are pharmaceuticals employed to manage infections caused by parasites, functioning by targeting the parasites’ biological processes and impeding their proliferation, reproduction, or viability within the host. For instance, in February 2024, Zydus Lifesciences Limited, an India-based pharmaceutical company, obtained World Health Organization (WHO) prequalification approval for the active pharmaceutical ingredient (API) and the formulation of miltefosine for managing leishmaniasis or kala-azar. Miltefosine is an oral antiparasitic drug that operates by disturbing the parasite’s cell membrane and interfering with its metabolism, ultimately leading to cell death. It further suppresses parasite growth and survival, establishing it as an effective oral treatment option for visceral leishmaniasis or kala azar.

Who Are The Top-Performing Companies In The Visceral Leishmaniasis Market In Recent Years?

Major companies operating in the visceral leishmaniasis market are Pfizer Inc., GSK plc, Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories, Aurobindo Pharma Limited, Cipla Limited, Zydus Lifesciences Limited, Glenmark Pharmaceuticals Limited, Alkem Laboratories Ltd., Xellia Pharmaceuticals, Gufic Biosciences Ltd., United Biotech Private Limited, DNDi, Sanofi SA, Bharat Serums and Vaccines Limited, Emcure Pharmaceuticals Limited, Hetero Drugs Limited, Lupin Limited, Ipca Laboratories Limited, Intas Pharmaceuticals Limited, Macleods Pharmaceuticals Limited, Mankind Pharma Limited, Alembic Pharmaceuticals Limited

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/visceral-leishmaniasis-global-market-report

Which Region Currently Holds The Largest Share Of The Visceral Leishmaniasis Market?

North America was the largest region in the visceral leishmaniasis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the visceral leishmaniasis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Visceral Leishmaniasis Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=23573&type=smp

Browse Through More Reports Similar to the Global Visceral Leishmaniasis Market 2026, By The Business Research Company

Veterinary Parasiticides Market Report 2026

https://www.thebusinessresearchcompany.com/report/veterinary-parasiticides-global-market-report

Anticoagulant Market Report 2026

https://www.thebusinessresearchcompany.com/report/anticoagulant-global-market-report

Psoriasis Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/psoriasis-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795